Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZG-005 (Primary)
  • Indications Cervical cancer; Cholangiocarcinoma; Neuroendocrine carcinoma; Rectal cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

  • 04 Jun 2024 Results (as of December 25, 2023; n=68) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 24 May 2024 Results presented in the Zelgen Pharmaceuticals Media Release.
  • 24 May 2024 According to a Zelgen Pharmaceuticals media release, as of April 16, 2024, the dose escalation phase of the ZG005-001 project has been completed, with a total of 32 subjects enrolled; the dose expansion phase is in progress, with 47 subjects enrolled. Among the 79 subjects, 43% of the subjects had previously received at least two lines of systemic treatment with anti-tumor drugs, and 48% of the subjects had previously received PD-1/PD-L1 inhibitors.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top